Cantargia Feed

2026-04-17 21:00:00 Cantargia Announces AACR 2026 Presentation of Study Design and Supportive Pre-Clinical Data for Investigator-Initiated Nadunolimab Study in MSS CRC

2026-04-17 21:00:00 Cantargia tillkännager AACR 2026 presentation av studiedesign och understödjande preklinisk data kring forskarledd nadunolimab studie i MSS CRC

2026-04-17 07:31:00 Cantargia publishes Annual Report 2025

2026-04-17 07:31:00 Cantargia publicerar Årsredovisning 2025

2026-04-17 07:30:00 Notice of annual general meeting in Cantargia AB (publ)

2026-04-17 07:30:00 Kallelse till årsstämma i Cantargia AB (publ)

2026-03-18 07:30:00 New preclinical data on anti-tumor effects of nadunolimab in metastatic colorectal cancer presented at the Keystone Cancer Immunotherapy conference 3,96 SEK | +1,80% | 12,8 MSEK

2026-03-18 07:30:00 Nya prekliniska resultat som visar tumörhämmande effekter av nadunolimab i metastatisk kolorektalcancer presenterades på Keystone konferensen för immunterapi i cancer 3,96 SEK | +1,80% | 12,8 MSEK

2026-03-05 10:00:00 Cantargia to participate at Van Lanschot Kempen’s Life Sciences Conference 4,22 SEK | +4,58% | 6,40 MSEK

2026-03-05 10:00:00 Cantargia deltar på Van Lanschot Kempens Life Sciences Conference 4,22 SEK | +4,58% | 6,40 MSEK

2026-02-23 09:00:00 Cantargia to participate in TD Cowen’s Annual Healthcare Conference 4,33 SEK | -3,13% | 12,4 MSEK

2026-02-23 09:00:00 Cantargia deltar på TD Cowens Annual Healthcare Conference 4,33 SEK | -3,13% | 12,4 MSEK

2026-02-20 07:00:00 Cantargia publishes Full Year Report 2025 4,47 SEK | -11,49% | 33,8 MSEK

2026-02-20 07:00:00 Cantargia publicerar bokslutskommuniké för 2025 4,47 SEK | -11,49% | 33,8 MSEK

2026-02-06 11:00:00 Invitation to the Presentation of Cantargia’s Annual Results for 2025 5,30 SEK | -1,85% | 6,18 MSEK

2026-02-06 11:00:00 Inbjudan till presentation av Cantargias bokslutskommuniké för 2025 5,30 SEK | -1,85% | 6,18 MSEK

2026-01-28 10:00:00 Cantargia to participate at Leerink Partners Global Healthcare Conference 5,45 SEK | -2,68% | 14,0 MSEK

2026-01-28 10:00:00 Cantargia deltar på Leerink Partners Global Healthcare Conference 5,45 SEK | -2,68% | 14,0 MSEK

2026-01-23 07:30:00 Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study 6,20 SEK | +1,64% | 37,6 MSEK

2026-01-23 07:30:00 Cantargia rapporterar första patienten doserad i ny forskarinitierad studie i kolorektal cancer i USA 6,20 SEK | +1,64% | 37,6 MSEK

2025-12-05 07:30:00 Cantargia rapporterar övergripande överlevnadsresultat från TRIFOUR 3,80 SEK | -14,12% | 82,4 MSEK

2025-12-05 07:30:00 Cantargia Provides Update on Overall Survival Data from TRIFOUR 3,80 SEK | -14,12% | 82,4 MSEK

2025-11-19 07:00:00 Cantargia Publishes Interim Report for January to September 2025 3,17 SEK | -7,45% | 21,0 MSEK

2025-11-19 07:00:00 Cantargia publicerar delårsrapport för januari till september 2025 3,17 SEK | -7,45% | 21,0 MSEK

2025-11-12 08:45:00 Cantargia presents Nomination Committee ahead of 2026 AGM 3,81 SEK | +5,25% | 13,0 MSEK

2025-11-12 08:45:00 Cantargia presenterar valberedning inför årsstämman 2026 3,81 SEK | +5,25% | 13,0 MSEK

2025-11-05 09:30:00 Inbjudan till presentation av Cantargias delårsrapport januari-september 2025 3,21 SEK | -2,13% | 9,39 MSEK

2025-11-05 09:30:00 Invitation to the Presentation of Cantargia’s Interim Report January-September 2025 3,21 SEK | -2,13% | 9,39 MSEK

2025-10-23 13:30:00 Cantargia to Participate in Upcoming Conferences 2,34 SEK | -2,09% | 4,80 MSEK

2025-10-23 13:30:00 Cantargia medverkar på kommande investerarkonferenser 2,34 SEK | -2,09% | 4,80 MSEK

2025-10-02 07:30:00 Cantargia appoints Dr. Wolfram Dempke as Chief Medical Officer 2,65 SEK | -5,36% | 5,48 MSEK

2025-10-02 07:30:00 Cantargia utser Dr Wolfram Dempke till Chief Medical Officer 2,65 SEK | -5,36% | 5,48 MSEK

2025-10-01 00:00:00 Cantargia presents data at an AACR Conference strengthening IL1RAP as a targetable hallmark in PDAC 2,56 SEK | -2,29% | 2,50 MSEK

2025-10-01 00:00:00 Cantargia presenterar data på en AACR-konferens som stärker IL1RAP som ett viktigt målprotein i PDAC 2,56 SEK | -2,29% | 2,50 MSEK

2025-09-11 07:30:00 Cantargia closes the acquisition of CAN10 by Otsuka 2,73 SEK | +2,44% | 32,0 MSEK

2025-09-11 07:30:00 Cantargia slutför Otsukas förvärv av CAN10 2,73 SEK | +2,44% | 32,0 MSEK

2025-08-27 07:30:00 Cantargia granted important US patent for nadunolimab 2,67 SEK | +5,31% | 29,0 MSEK

2025-08-27 07:30:00 Cantargia erhåller viktigt patent i USA för nadunolimab 2,67 SEK | +5,31% | 29,0 MSEK

2025-08-21 07:00:00 Cantargia publishes half-year report 2025 2,67 SEK | -3,61% | 11,4 MSEK

2025-08-21 07:00:00 Cantargia publicerar halvårsrapport 2025 2,67 SEK | -3,61% | 11,4 MSEK

2025-08-18 18:25:00 Cantargia appoints Dr Hilde Steineger as Chief Executive Officer 2,89 SEK | +1,40% | 9,12 MSEK

2025-08-18 18:25:00 Cantargia utnämner Dr Hilde Steineger till verkställande direktör 2,89 SEK | +1,40% | 9,12 MSEK

2025-08-12 10:15:00 Invitation to the presentation of Cantargia’s H1 2025 report 2,98 SEK | -2,61% | 4,99 MSEK

2025-08-12 10:15:00 Inbjudan till presentation av Cantargias halvårsrapport 2025 2,98 SEK | -2,61% | 4,99 MSEK

2025-07-17 21:30:00 Cantargia announces preliminary topline efficacy results from the phase 2 TRIFOUR trial of nadunolimab in advanced triple-negative breast cancer (TNBC) 2,67 SEK | -29,55% | 75,8 MSEK

2025-07-17 21:30:00 Cantargia meddelar preliminära topline-effektresultat från fas 2-studien TRIFOUR med nadunolimab i avancerad trippelnegativ bröstcancer (TNBC) 2,67 SEK | -29,55% | 75,8 MSEK

2025-07-16 14:15:00 Cantargia announces publication of clinical data showing benefit of nadunolimab combination therapy in advanced lung cancer 3,88 SEK | -3,61% | 226 MSEK

2025-07-16 14:15:00 Cantargia meddelar publicering av kliniska data som visar fördel av kombinationsbehandling med nadunolimab i avancerad lungcancer 3,88 SEK | -3,61% | 226 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Cantargia

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden